[1] Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord,2022,22(1):63-72. [2] Sara V, Giuseppe L, Margherita F, et al. Once-weekly subcutaneous semaglutide improves fatty liver disease in patients with type 2 diabetes: a 52-week prospective real-life study. Nutrients,2022,14(21):4673. [3] 刘岗,张浩,胡峻, 非酒精性脂肪性肝病患者血清 miR-183-5p 和miR-96-5p 水平变化及其临床意义探讨.实用肝脏病杂志,2023,26(2):197-201. [4] Li N, Yin L, Shang JM, et al. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the sirt1/AMPK signaling pathway.Biomed Pharmacother,2023,165:115113. [5] Xu F, Li Z, Zheng XB, et al. Sirt1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes,2014,63(11):3637-3646. [6] Salman M, Kamel MA, El-Nabi SEH, et al. The regulation of hbp1, sirt1, and srebp1c genes and the related micro RNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis. Plos One,2022,17(4):e0265455. [7] Liou CJ, Lee YK, Ting NC, et al. Protective effects of licochalcone A ameliorates obesity and non-alcoholic fatty liver disease via promotion of the sirt1/ampk pathway in mice fed a high-fat diet. Cells,2019,8(5):447-467. [8] Nagai Y, Yonemitsu S, Erion DM, et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab,2009,9:252-264. [9] 邢英,李雅丽,郑嵘炅, 利拉鲁肽对非酒精性脂肪肝大鼠胰岛素抵抗的改善作用. 实用肝脏病杂志,2017,20(6):668-672. [10] Cho EEL, Ang CZ, Quek JX, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut,2023,72(11):2138-2148. [11] Caturano A, Acierno C, Nevola R, et al. Non-alcoholic fatty liver disease: from pathogenesis to clinical impact. Processes,2021,9(1):135. [12] Cegla J. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomized, placebo-controlled phase 2 study. Ann Clin Biochem,2016,53(4):518. [13] Powell EE, Wong VWS, Rinella M, Non-alcoholic fatty liver disease. Lancet,2021,397(10290):2212-2224. [14] Oliveira FCB, Bauer EJ, Ribeiro CM, et al. Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue. Front Endocrinol. 2022,12:803363. [15] Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor based therapeutics for metabolic liver disease. Endocr Rev,2023,44(1):14-32. [16] Anggreini P, Kuncoro H, Sumiwi SA, et al. Role of the ampk/sirt1 pathway in nonalcoholic fatty liver disease. Mol Med Rep,2023,27(2):35-46. [17] Côté CD, Rasmussen BA, Duca FA. Resveratrol activates duodenal sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med,2015,21(5):498-505. [18] Kadono K, Kageyama S, Nakamura K, et al. Myeloid ikaros-sirt1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver. J Hepatol,2022,76(4):896-909. [19] Xiang J, Qin LY, Zhong JL, et al. GLP-1ra liraglutide and semaglutide improves obesity-induced muscle atrophy via sirt1 pathway. Diabetes Metab Syndr Obes,2023,16:2433-2446. [20] Fang CQ, Pan JH, Qu N, et al. The ampk pathway in fatty liver disease. Front Physiol,2022,13:970292. |